Antidiabetic medications for weight loss
Pro Research Analysisby 
Searched over 200M research papers
Antidiabetic Medications and Weight Loss: Key Drug Classes
Obesity is a common comorbidity in people with type 2 diabetes, and certain antidiabetic medications can help with weight loss while managing blood sugar levels. The effectiveness of these medications for weight loss varies by drug class and individual agent 127.
GLP-1 Receptor Agonists for Weight Loss
Glucagon-like peptide-1 (GLP-1) receptor agonists are among the most effective antidiabetic medications for weight loss. Drugs like liraglutide, semaglutide, and tirzepatide have shown strong weight loss effects, often resulting in more than 5% reduction in initial body weight 12410. Semaglutide, in particular, has demonstrated superior weight loss compared to other antidiabetic medications and is FDA-approved for chronic weight management under the brand name Wegovy . Exenatide, another GLP-1 agonist, produces mild weight loss .
SGLT-2 Inhibitors and Moderate Weight Loss
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are associated with moderate weight loss, typically between 3.2% and 5% of initial body weight 1279. These agents are effective in both type 2 and, as adjuncts to insulin, type 1 diabetes, though their use in type 1 diabetes may carry a higher risk of diabetic ketoacidosis .
Metformin and Acarbose: Mild Weight Loss
Metformin, a first-line oral antidiabetic medication, is associated with mild weight loss and is sometimes used off-label for weight management, though it is not officially approved for this purpose 1278. Acarbose also produces mild weight loss effects 12.
DPP-4 Inhibitors: Neutral to Mild Effects
Dipeptidyl peptidase-4 (DPP-4) inhibitors generally have a neutral or only mild effect on weight, making them less suitable for patients seeking significant weight loss 27.
Real-World Evidence and Combination Therapies
Real-world data confirm that patients using antidiabetic medications associated with weight loss, such as SGLT-2 inhibitors and metformin, experience significant reductions in weight, HbA1c, and waist circumference . Combination therapies, such as dapagliflozin with liraglutide, can further enhance weight loss and glycemic control, though safety considerations like the risk of diabetic ketoacidosis must be managed .
New Developments: CagriSema and Future Prospects
Emerging therapies like CagriSema, which combines a GLP-1 agonist (semaglutide) with an amylin analog (cagrilintide), are being investigated for their potential to provide even greater weight loss and glycemic control . Early results are promising, and future trials will clarify their role in obesity and diabetes management.
Conclusion
GLP-1 receptor agonists (especially semaglutide, liraglutide, and tirzepatide) are the most effective antidiabetic medications for weight loss, followed by SGLT-2 inhibitors for moderate effects, and metformin or acarbose for mild effects. DPP-4 inhibitors are generally weight neutral. Combination therapies and new agents like CagriSema may offer additional benefits. The choice of medication should consider both glycemic control and weight management goals, as well as individual patient risk factors and preferences 1245+5 MORE.
Sources and full results
Most relevant research papers on this topic